Establishment of new classification in myeloid neoplasms for personalized medicine
Project/Area Number |
21591206
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Hematology
|
Research Institution | Hiroshima University |
Principal Investigator |
HARADA Hironori 広島大学, 原爆放射線医科学研究所, 講師 (10314775)
|
Co-Investigator(Kenkyū-buntansha) |
HARADA Yuka 広島大学, 原爆放射線医科学研究所, 助教 (50379848)
|
Project Period (FY) |
2009 – 2011
|
Project Status |
Completed (Fiscal Year 2011)
|
Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2011: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2010: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2009: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
Keywords | 骨髄球系造血器腫瘍 / 骨髄異形成症候群 / 遺伝子変異 / 転写因子 / RUNX1遺伝子変異 / GATA2遺伝子変異 / BMI1 / ヒト造血幹細胞 / 急性前骨髄球性白血病 / AML1/RUNX1遺伝子 / 急性骨髄性白血病 / CEBPA遺伝子 / 骨髄増殖性腫瘍 / AML1 / RUNX1遺伝子 |
Research Abstract |
We analyzed gene abnormalities that may play a central role for the pathogenesis in myelodysplastic syndromes(MDS) and acute myeloid leukemias. Gene mutations of hematopoietic transcriptional factors RUNX1, CEBPA and GATA2 have been detected. Moreover, we clarified that the mutants had a potential to develop MDS by using human hematopoietic stem cells and mouse bone marrow transplantation model. Therefore, we proposed that the mutations of RUNX1, CEBPA and GATA2 are the master gene mutations for the pathogenesis of MDS.
|
Report
(4 results)
Research Products
(139 results)
-
[Journal Article] Morphologic analysis in myelodysplastic syndromes with del(5q) treated with lenalidomide2012
Author(s)
Matsuda A, Taniwaki M, Jinnai I, HaradaH, Watanabe M, Suzuki K, Yanagita S, SuzukiT, Yoshida Y, Kimura A, Tsudo M, TohyamaK, Takatoku M, Ozawa K
-
Journal Title
A Japanese multi-institutional study. LeukRes
Volume: 36(5)
Pages: 575-580
Related Report
Peer Reviewed
-
-
[Journal Article] Fynis not essential for Bcr-Abl-induced leukemogenesis in mouse bone marrow transplantation models2012
Author(s)
Doki N, Kitaura J, Inoue D, Kato N, Kagiyama Y, Uchida T, Togami K, Isobe M, Ito S, Maehara A, Izawa K, Oki T, HaradaY, Nakahara F, Harada H, Kitamura T
-
Journal Title
Int J Hematol
Volume: 95(2)
Pages: 167-175
Related Report
Peer Reviewed
-
-
-
[Journal Article] Fyn is not essential for Bcr-Ab1-induced leukemogenesis in mouse bone marrow transplantation models2012
Author(s)
Doki N, Kitaura J, Inoue D, Kato N, Kagiyama Y, Uchida T, Togami K, Isobe M, Ito S, Maehara A, Izawa K, Oki T, Harada Y, Nakahara F, Harada H, Kitamura T
-
Journal Title
Int J Hematol
Volume: 95(2)
Issue: 2
Pages: 167-175
DOI
Related Report
Peer Reviewed
-
[Journal Article] Aberrant expression of RasGRP1 cooperates with gain-of-function NOTCH1 mutations in T-cell leukemogenesis2012
Author(s)
Oki T, Kitaura J, Watanabe-Okochi N, Nishimura K, Maehara A, Uchida T, Komeno Y, Nakahara F, Harada Y, Sonoki T, Harada H, Kitamura T
-
Journal Title
Leukemia
Volume: (in press)
Issue: 5
Pages: 1038-1045
DOI
Related Report
Peer Reviewed
-
[Journal Article] Morphologic analysis in myelodysplastic syndromes with del(5q) treated with lenalidomide. A Japanese multiinstitutional study2012
Author(s)
Matsuda A, Taniwaki M, Jinnai I, Harada H, Watanabe M, Suzuki K, Yanagita S, Suzuki T, Yoshida Y, Kimura A, Tsudo M, Tohyama K, Takatoku M, Ozawa K
-
Journal Title
Leuk Res
Volume: (in press)
Issue: 5
Pages: 575-580
DOI
Related Report
Peer Reviewed
-
-
-
[Journal Article] Two typesof C/ EBP mutations play distinct but collaborative roles in leukemogenesis2011
Author(s)
Kato N, Kitaura J, Doki N, Komeno Y, Watanabe-Okochi N, Togami K, Nakahara F, Oki T, Enomoto Y, Fukuchi Y, Nakajima H, Harada Y, Harada H, Kitamura T
-
Journal Title
lessons from clinical data and BMT models. Blood
Volume: 117
Pages: 221-233
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
[Journal Article] AID-inducedT-lymphoma or B-leukemia/ lymphoma in amouse BMT model.2010
Author(s)
Komeno Y, Kitaura J, Watanabe-OkochiN, Kato N, Oki T, Nakahara F, Harada Y, Harada H, Shinkura R, Nagaoka H, HayashiY, Honjo T, Kitamura T
-
Journal Title
Leukemia
Volume: 24(5)
Pages: 1018-1024
Related Report
Peer Reviewed
-
[Journal Article] Hes1 immortalizes committed progenitors and plays a role in blast crisis transitionin chronic myelogenous leukemia2010
Author(s)
Nakahara F, Sakata-Yanagimoto M, Komeno Y, Kato N, Uchida T, Haraguchi K, Kumano K, Harada Y, Harada H, Kitaura J, Ogawa S, Kurokawa M, Kitamura T, Chiba S
-
Journal Title
Blood
Volume: 115(14)
Pages: 2872-2881
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
[Journal Article] Lenalidomide is active in Japanesepatients with symptomatic anemia in low-or Intermediate I risk myelodysplastic syndrome(MDS) with a deletion 5qabnormality2009
Author(s)
Harada H, Watanabe M, Suzuki K, Yamagata S, Suzuki T, Yoshida Y, Kimura A, Tsudo M, Matsuda A, Tohyama K, Taniwaki M, Takeshita K, Takatoku M, Ozawa K
-
Journal Title
Int J Hematol
Volume: 90(3)
Pages: 353-360
Related Report
Peer Reviewed
-
[Journal Article] Possible involvement of RasGRP4 in leukemogenesis2009
Author(s)
Watanabe-Okochi N, Oki T, Komeno Y, Kato N, Yuji K, Ono R, Harada Y, Harada H, Hayashi Y, Nakajima H, Nosaka T, KitauraJ, Kitamura T
-
Journal Title
Int J Hematol
Volume: 89(4)
Pages: 470-481
NAID
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
[Presentation] Deferasirox improved cytopenia inpatients with bone marrow failure2011
Author(s)
Harada Y, Okikawa Y, Kimura A, Ito T, Niimi H, Noda M, Tanaka H, Shimomura T, Kuroda Y, Katsutani S, Kimura A, Harada H
Organizer
73rdAnnual Meeting of the Japanese Society ofHematology
Place of Presentation
Nagoya
Related Report
-
-
-
[Presentation] Long-term follow up data of cytogeneticresponse in Japanese low/ lnt-1 MDSpatients with del(5q)2011
Author(s)
Taniwaki M, Chinen Y, Harada H, Watanabe M, Suzuki K, Yanagida S, ShimadaH, Suzuki T, Yoshida Y, Kimura A, Tsudo M, Matsuda A, Tohyama K, Takatoku M, Ozawa K
Organizer
The 73rd AnnualMeeting of the Japanese Society ofHematology
Place of Presentation
Nagoya
Related Report
-
-
-
-
-
-
-
[Presentation] Long-term follow up data of cytogenetic response in Japanese low/lnt-1 MDS patients with del(5q)2011
Author(s)
Taniwaki M, Chinen Y, Harada H, Watanabe M, Suzuki K, Yanagida S, Shimada H, Suzuki T, Yoshida Y, Kimura A, Tsudo M, Matsuda A, Tohyama K, Takatoku M, Ozawa K
Organizer
第73回日本血液学会学術集会
Place of Presentation
名古屋市
Related Report
-
-
-
[Presentation] Deferasirox improved cytopenia in patients with bone marrow failure2011
Author(s)
Harada Y, Okikawa Y, Kimura A, Ito T, Niimi H, Noda M, Tanaka H, Shimomura T, Kuroda Y, Katsutani S, Kimura A, Harada H
Organizer
第73回日本血液学会学術集会
Place of Presentation
名古屋市
Related Report
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
[Presentation] Lenalidomide inJapanese Patients with Symptomatic anemiain Low or Int-1 Risk MDS with deletion 5q.2009
Author(s)
Watanabe M, Harada H, Suzuki K, Yanagita S, Suzuki T, Yoshida Y, Tsudo M, Kimura A, Matsuda A, Tohyama K, TaniwakiM, Takatoku M, Ozawa K
Organizer
71st Annual Meeting of Japanese Society of Hematology
Place of Presentation
Kyoto
Related Report
-
-
-
-
-
[Presentation] Results ofPhase II Clinical Study of Lenalidomide in Japanese Patients with Myelodysplastic Syndrome(MDS)2009
Author(s)
Harada H, Watanabe M, Suzuki K, Yanagita S, Suzuki T, Yoshida Y, Kimura A, Tsudo M, Takatoku M, Ozawa K
Organizer
The 10th InternationalSymposium on Myelodysplastic Syndromes(MDS2009)
Place of Presentation
Patras, Greece
Related Report
-
-
-
-
-
-
-
-
-
-
-
-